Superstring Capital Management LP
Superstring Capital Management LP reported 35 holdings worth US$200M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Superstring Capital Management LP reported 35 holdings worth US$200M as of Sep 30, 2026. Largest: Cogent Biosciences, Inc., Axsome Therapeutics, Inc. and Trevi Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 35
- Value as reported
- US$200M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cogent Biosciences, Inc. | 597K | US$19.1M | 9.6% |
| Axsome Therapeutics, Inc. | 102K | US$18.9M | 9.5% |
| Trevi Therapeutics, Inc. | 985K | US$14.1M | 7.1% |
| Genmab A/S | 366K | US$13M | 6.5% |
| Climb Bio, Inc. | 918K | US$10.5M | 5.3% |
| Zai Lab Ltd. | 363K | US$9.55M | 4.8% |
| Adlai Nortye Group Ltd. | 588K | US$9.41M | 4.7% |
| Revolution Medicines, Inc. | 41,784 | US$8.58M | 4.3% |
| Celldex Therapeutics, Inc. | 242K | US$7.86M | 3.9% |
| Immunovant, Inc. | 222K | US$7.5M | 3.8% |
| United Therapeutics Corporation | 13,321 | US$7.22M | 3.6% |
| Legend Biotech Corp. | 357K | US$7.11M | 3.6% |
| Definium Therapeutics, Inc. | 177K | US$6.72M | 3.4% |
| Roivant Sciences Ltd. | 179K | US$6.54M | 3.3% |
| Vir Biotechnology, Inc. | 579K | US$6.47M | 3.2% |
| Ionis Pharmaceuticals, Inc. | 132K | US$5.91M | 3.0% |
| Savara, Inc. | 1.02M | US$5.25M | 2.6% |
| Sagimet Biosciences Inc. - Series A | 423K | US$4.18M | 2.1% |
| Abivax SA | 30,020 | US$2.97M | 1.5% |
| Ginkgo Bioworks Holdings, Inc. | 223K | US$2.86M | 1.4% |
| Spyre Therapeutics, Inc. | 30,022 | US$2.67M | 1.3% |
| Bright Minds Biosciences Inc. | 48,045 | US$2.39M | 1.2% |
| Taysha Gene Therapies, Inc. | 413K | US$2.01M | 1.0% |
| Latigo Biotherapeutics, Inc. | 88,178 | US$1.47M | 0.74% |
| Oruka Therapeutics, Inc. | 15,446 | US$1.29M | 0.64% |
| MapLight Therapeutics, Inc. | 118K | US$1.21M | 0.60% |
| Madrigal Pharmaceuticals, Inc. | 2,099 | US$1.06M | 0.53% |
| Cabaletta Bio, Inc. | 517K | US$993K | 0.50% |
| Xenon Pharmaceuticals Inc. | 26,496 | US$985K | 0.49% |
| Tonix Pharmaceuticals Holding Corp. | 74,688 | US$727K | 0.36% |
| Boundless Bio, Inc. | 206K | US$518K | 0.26% |
| GRAIL, Inc. | 3,238 | US$454K | 0.23% |
| Biomea Fusion, Inc. | 226K | US$44,565 | 0.02% |
| Aclaris Therapeutics, Inc. | 0 | US$0 | 0.00% |
| BeOne Medicines Ltd. Class A | 0 | US$0 | 0.00% |
| Cybin, Inc. | 0 | US$0 | 0.00% |
| Sensei Biotherapeutics, Inc. | 0 | US$0 | 0.00% |
| ORIC Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Protara Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Sionna Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Vaxcyte, Inc. | 0 | US$0 | 0.00% |
| VYNE Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related